SBE 13 hydrochloride
Cat. No. 4292
Chemical Name: N-[[4-[(6-Chloro-3-pyridinyl)methox
Biological ActivitySelective inhibitor of PLK1 (IC50 values are 200 pM, 875 nM and 66 μM for PLK1, PLK3 and PLK2 respectively). Exhibits no effect on Aurora kinase A activity. Binds and stabilizes the inactive form of PLK1. Delays cell cycle progression, reduces cell proliferation and induces apoptosis in a range of human cancer cell lines. Transiently arrests cells cycle at G0/G1 in primary cells.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Keppner et al (2011) Fate of primary cells at the G1/S boundary after Polo-like kinase 1 inhibition by SBE13. Cell Cycle 10 708. PMID: 21301227.
Eckerdt (2010) Freezing Polo in its sleep: targeting the inactive conformation of Polo-like kinase 1 in cancer cells. Cell Cycle 9 (5) 862. PMID: 20348843.
Keppner et al (2010) Biological impact of freezing Plk1 in its inactive conformation in cancer cells. Cell Cycle 9 761. PMID: 20139717.
Liu (2010) SBE13 joins the family of Polo-like kinase 1 (Plk1) inhibitors. Cell Cycle 9 445. PMID: 20130451.
Keppner et al (2009) Identification and validation of a potent type II inhibitor of inactive polo-like kinase 1. ChemMedChem 4 1806. PMID: 19746360.
If you know of a relevant reference for SBE 13 hydrochloride please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses SBE 13 hydrochloride from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: SBE 13 hydrochloride, supplier, SBE13, polo-like, kinases, plk1, plk, selective, potent, Tocris Bioscience, Polo-like Kinase Inhibitor products
Find multiple products by catalog number
New Products in this Area
ATP-competitive inhibitor of DAPK and ZIPKst-Ht31 P
Negative control for st-Ht31 (Cat. No. 6286)st-Ht31
Inhibits PKA/AKAP interactions; cell permeableP21d hydrochloride
Potent and selective Brk inhibitorCVT 313
High affinity PKC activator; also APP modulatorJH 295
Irreversible Nek2 inhibitorOXSI 2
Potent Syk kinase inhibitor; also inhibits assembly of NLRP3 inflammasomesSTK16-IN-1
Serine/threonine protein kinase 16 (STK16) inhibitor; also inhibits PI 3Kδ, PI 3Kγ and mTOR kinases.AZ PFKFB3 26
Potent and selective PFKFB3 inhibitorNCL 00017509
Potent and reversible NIMA related kinase 2 (Nek2) inhibitorXMD 8-87
Potent Ack1/TNK2 inhibitorSKI 178
Non-lipid sphingosine kinase 1 (SphK1) inhibitorML 315 hydrochloride
Inhibitor of Clk and DYRK kinasesEverolimus
mTOR inhibitor;immunosuppressantPKI (5-24)
High affinity PKA inhibitorTDZD 8
Selective non-ATP competitive inhibitor of GSK 3βBI 605906
Selective IKKβ inhibitorGSK 319347A
Potent and selective IKKε inhibitorFRAX 597
Potent group I PAK inhibitorMRT 68921 dihydrochloride
Potent ULK inhibitor; inhibits autophagyAM 2394
Potent glucokinase activator; orally bioavailableeCF 309
Potent mTOR inhibitorPF 3758309 dihydrochloride
Potent PAK4 inhibitor; orally availableAZ Dyrk1B 33
Potent and selective Dyrk1B kinase inhibitor
September 27 - 30, 2017